ANI Pharmaceuticals Launches FutureVision Advisory Council to Transform Ophthalmology
Minnesota, Tuesday, 2 December 2025.
ANI Pharmaceuticals unveils the FutureVision Advisory Council, composed of leading retina and uveitis specialists, to drive innovation and strategic growth in ophthalmology, enhancing patient care.
Formation of the Advisory Council
On December 2, 2025, ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced the formation of the FutureVision Advisory Council, a strategic move to bolster its ophthalmology and retina franchise. The council is comprised of seven retina specialists and three uveitis specialists, all globally recognized leaders in their fields. This initiative underscores ANI’s dedication to innovation within the ophthalmology sector and aims to address critical market needs by enhancing patient care [1].
Leadership and Strategic Goals
The FutureVision Advisory Council is co-led by Arshad M. Khanani, MD, MA, FASRS, and Peter Y. Chang, MD, FACS. Dr. Khanani, serving as Principal Retina Advisor and Chair, emphasized ANI’s commitment to the eye care community. He expressed his honor in leading the council alongside esteemed colleagues, aiming to guide ANI’s future innovations toward areas of greatest patient need. Dr. Chang, Principal Uveitis Advisor and Chair, shared his enthusiasm for collaborating with the council to explore strategic opportunities that could benefit patients with ocular diseases [1].
Council Members and Expertise
The retina specialists on the council include Dr. Arshad M. Khanani, Dr. Ashkan M. Abbey, Dr. David A. Eichenbaum, Dr. Yasha S. Modi, Dr. Christopher D. Riemann, Dr. Lejla Vajzovic, and Dr. Christina Y. Weng. The uveitis specialists are Dr. Peter Y. Chang, Dr. Thomas Albini, and Dr. Rajiv Shah. These members bring a wealth of expertise and are expected to significantly contribute to ANI’s strategic growth and innovation in the field of ophthalmology [1].
Impact on ANI Pharmaceuticals
This strategic initiative aligns with ANI Pharmaceuticals’ broader goals of expanding its footprint in the rare disease market, particularly in ophthalmology. By leveraging the expertise of the FutureVision Advisory Council, ANI aims to enhance its product offerings and improve patient outcomes. This move is indicative of ANI’s proactive approach towards addressing market demands and reinforces its position as a leader in the development of therapeutics for eye care [1].